Hypertension and rarefaction during treatment with telatinib, a Small molecule angiogenesis inhibitor

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3470-3476

  Steeghs, Neeltje ^a,b,c   Gelderblom, Hans ^a   Roodt, Jos OP'T ^b   Christensen, Olaf ^d   Rajagopalan, Prabhu ^d   Hovens, Marcel ^b   Putter, Hein ^c   Rabelink, Ton J ^b   De Koning, Eelco ^b  

^a Departments of Clinical Oncology   (Netherlands)

^b Department of Nephrology ^*  (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BAY 57 9352; GLYCERYL TRINITRATE; TELATINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CANCER PATIENT; CAPILLARY DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HYPERTENSION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; PULSE WAVE; SKIN BLOOD FLOW; SOLID TUMOR; SYSTOLIC BLOOD PRESSURE; VASODILATATION; BLOOD PRESSURE; BLOOD VESSEL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; LASER DOPPLER FLOWMETRY; MIDDLE AGED; NEOPLASM; PATHOLOGY; SKIN; VASCULARIZATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BLOOD PRESSURE; BLOOD VESSELS; FEMALE; HUMANS; HYPERTENSION; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN-TYROSINE KINASES; SKIN; VASODILATION;

EID: 50349101200     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5050     Document Type: Article

References (40)

1. Pisacane AM, Risio M, VEGF and VEGFR-2 immuno-histochemistry in human melanocyte naevi and cutaneous melanomas. Melanoma Res 2005;15:39-43.
2. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angio-genesis. J Clin Oncol 2005:23:1011 -27.
3. Raben D, Helfrich B. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer? Clin Lung Cancer 2004;6:48-57.
4. Giatromanolaki A, Koukourakis Ml, Turley H, Sivridis E, Harris AL, Gatter KC. Phosphorylated KDR expression in endometrial cancer cells relates to HIF1 α/VEGF pathway and unfavourable prognosis. Mod Pathol 2006:19:701-7.
5. Xia G, Kumar SR, Hawes D, et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006:175:1245-52.
6. Amino N, Ideyama Y, Yamano M, et al. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res 2006;12:1630-8.
7. Verheul HM, Pinedo HM. Inhibition of angiogenesis in cancer patients. Expert Opin Emerg Drugs 2005:10: 403-12.
8. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7:193-201.
9. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24:1363-9.
10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Beva-cizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
11. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-8.
12. Motzer RJ, Hutson TE. Tomczak P, et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med 2007:356:115-24.
13. Mourad JJ, des GG, Debbabi H, Levy Bl. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2007 Dec 4 Epub ahead of print.
14. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-95.
15. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475-85.
16. Gelderblom H, Verweij J, Steeghs N, et al. Phase I. safety, pharmacokinetic and biomarker study of telati-nib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continous schedule in patients with advanced solid tumors. Eur J Cancer Suppl 2007:4:25.
17. Van Bortel LM, Balkestein EJ, van Der Heijden-Spek JJ, et al. Non-invasive assessment of local arterial pulse pressure: comparison of applanation tonometry and echo-tracking. J Hypertens 2001;19:1037-44.
18. Cracowski JL, Minson CT, Salvat-Melis M, Halliwill JR. Methodological issues in the assessment of skin microvascular endothelial function in humans. Trends Pharmacol Sci 2006;27:503-8.
19. GronerW,WinkelmanJW, HarrisAG, et al.Orthogonal polarization spectral imaging: a new method for study of the microcirculation. Nat Med1999;5:1209-12.
20. Ince C. The microcirculation is the motor of sepsis. Crit Care 2005:9 Suppl 4:S13-9.
21. Meredith IT, Currie KE, Anderson TJ, Roddy MA, Ganz P, Creager MA. Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide. Am J Physiol 1996;270:H1435-40.
22. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995:91: 1314-9.
23. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006:5:4.
24. Ducharme A, Dupuis J, McNicoll S, Harel F, Tardif JC. Comparison of nitroglycerin lingual spray and sublingual tablet on time of onset and duration of brachial artery vasodilation in normal subjects. Am J Cardiol 1999;84:952-4.
25. Khoshdel AR, Thakkinstian A, Carney SL, Attia J. Estimation of an age-specific reference interval for pulse wave velocity: a meta-analysis. J Hypertens 2006;24:1231-7.
26. Boutouyrie P, Tropeano Al, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002:39:10-5.
27. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients Hypertension 2001;37:1236-41.
28. Stefanadis C, Vlachopoulos C, Karayannacos P. et al. Effect of vasa vasorum flow on structure and function of the aorta in experimental animals. Circulation 1995;91:2669-78.
29. Koller A. Signaling pathways of mechanotransduction in arteriolar endothelium and smooth muscle cells in hypertension. Microcirculation 2002:9:277-94.
30. le Noble FA, Stassen FR, Hacking WJ, Struijker Boudier HA. Angiogenesis and hypertension J Hypertens 1998;16:1563-72.
31. Hutchins PM, Lynch CD, Cooney PT, Curseen KA. The microcirculation in experimental hypertension and aging Cardiovasc Res 1996;32:772-80.
32. Sullivan JM, Prewitt RL, Josephs JA. Attenuation of the microcirculation in young patients with high-output borderline hypertension. Hypertension 1983:5:844 - 51.
33. Noon JP, Walker BR, Webb DJ, et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure J Clin Invest 1997;99:1873-9.
34. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-34.
35. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromo-some-positiveALL. N Engl J Med 2006:354:2542 - 51.
36. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis Cell 2007;130:691-703.
37. Zhu X.Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49:186-93.
38. Vuorela P, Helske S, Hornig C, Alitalo K, Weich H, Halmesmaki E. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia Obstet Gynecol 2000;95:353-7.
39. Kincaid-Smith P. The renal lesion of preeclampsia revisited. Am J Kidney Dis 1991:17:144-8.
40. Eremina V, Sood M, Haigh J, et al. Glomerular-spe-cific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases J Clin Invest 2003:111:707-16.